Biotest AG (BIESF) Research

Biotest Aktiengesellschaft, a German biopharmaceutical company established in Dreieich in 1946, specializes in the research, development, production, and global commercialization of advanced biological therapeutics. Its operations are organized into key segments: Therapy, Plasma & Services, and Other. The company’s primary focus areas encompass critical medical needs within hematology (blood disorders), clinical immunology, and intensive care medicine. Biotest offers a comprehensive range of products, including specific treatments for hemophilia like Haemoctin and Vihuma for the acute and prophylactic management of hemophilia A, and Haemonine for similar applications in hemophilia B. Its portfolio also features immunotherapies such as Cytotect CP biotest for cytomegalovirus infections, Fovepta for hepatitis B prophylaxis in neonates, and Hepatect for preventing hepatitis B reinfection. Varitect addresses varicella zoster virus infections, while Intratect and IgG Next Generation are utilized for primary immune and secondary antibody deficiency syndromes, autoimmune conditions, and certain neurological indications. Additionally, Zutectra is available for hepatitis B re-infection prophylaxis following liver transplantation. Further extending its product line, Biotest provides solutions like Albiomin and Biseko to restore and sustain circulating blood volume, Cofact for clotting factor deficiencies, and Fibrinogen for congenital fibrinogen deficiency. Innovative treatments include Trimodulin for community-acquired pneumonia and COVID-19, as well as Pentaglobin for bacterial infections. Known as Biotest Serum-Institut GmbH until its renaming in 1986, the company has been operating as a subsidiary of Grifols, S.A. since January 21, 2022.

Open Biotest AG (BIESF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.